Why Summit Therapeutics (SMMT) Is Up 9.6% After Phase III Ivonescimab Data Revealed at IASLC 2025

• Summit Therapeutics hosted a call to discuss Phase III clinical trial data for ivonescimab in non-small cell lung cancer, presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona.
• The new data, which includes results from both global and China-based studies, directly compares ivonescimab to standard-of-care treatments across a range of NSCLC patient populations, highlighting the therapy's potential reach and clinical relevance.
• We'll explore how presenting Phase III results for ivonescimab versus standard-of-care therapies informs Summit Therapeutics' evolving investment narrative.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Summit Therapeutics' Investment Narrative?

To be a shareholder in Summit Therapeutics, you need to believe that its pipeline, anchored by ivonescimab, can cross the high hurdles of clinical validation and regulatory approval, ultimately leading to meaningful commercial success. The latest call discussing new Phase III data directly addresses a crucial short-term catalyst: whether ivonescimab can compete with, or even surpass, established standards of care in NSCLC. This news event may impact the near-term narrative, as it brings more clarity on trial results and addresses key clinical questions investors have been waiting for. However, given Summit remains unprofitable (posting a US$565.71 million net loss last quarter) and has less than a year of cash runway, the business still faces pressing risks around funding and profitability. Commercialization timelines and partner support remain equally critical levers after this update. But the company’s limited cash runway could quickly turn investor optimism into concern.

Summit Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community cluster between US$15.97 and US$159.70 per share, highlighting stark differences among private investors. While opinions are wide ranging, most remain focused on upcoming clinical and funding milestones, which could shape Summit’s future trajectory. Explore this diversity of views to gauge what others are seeing that you may have missed.

Explore 6 other fair value estimates on Summit Therapeutics - why the stock might be worth over 6x more than the current price!

Build Your Own Summit Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Summit Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Summit Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Summit Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com